Abstract: A sustained-release preparation of indomethacin or interferon comprising the active ingredient in admixture with a pharmaceutically acceptable biodegradable carrier, particularly a carrier selected from collagen, gelatin, and a mixture thereof. The preparation is particularly suitable for parenteral administration and can release the active ingredient in an effective amount for a long period of time.

Abstract: A method for preparing a sustained release formulation utilizing collagen and/or gelatin as a carrier, which comprises the steps:(i) preparing a uniform and high concentrated mixture with respect to the collagen and/or gelatin by blending an active ingredient, said collagen and/or gelatin, and water or an admixture consisting of water and a hydrophilic organic solvent under one of the conditions selected from:(A) the pH of the mixture is kept below 5 and the salt concentration of the mixture is retained below fiber-forming concentration;(B) chemically modified collagen and/or gelatin is employed; and(C) glucose is added to the mixture;(ii) molding the resultant mixture; and(iii) gradually eliminating the solvent from the molded product.

Abstract: A solid sustained-release preparation in the form of a needle-like or bar-like shape, which consists essentially of an active ingredient and a pharmaceutically acceptable biodegradable carrier (e.g. proteins, preferably collagen, gelatin, and a mixture thereof). The sustained-release preparation can be administered to the body or implanted into the body by injection or an injection-like method and can release the active ingredient at an effective level for a long period of time when administered.

Abstract: A pharmaceutical composition is provided herein containing as a key ingredient 4-carbamoyl-imidazolium-5-oleate of the formula (I) ##STR1## its salt or hydrate thereof, and one or more of a sulfur compound capable of producing at least one of the ions selected from HSO.sub.3.sup.--, SO.sub.3.sup.2-- and S.sub.2 O.sub.5.sup.2--. The sulfur compounds prevent discoloration of the composition.The stabilization against coloration is further enhanced by the presence of L-cysteine hydrochloride. The solubility of the compound (I) can be further enhanced by the presence of a basic substance. The active ingredient is known as a therapeutic agent for the treatment of such diseases as rheumatism and nephritis.

Abstract: A composition comprising as the pharmaceutically active ingredient bencyclane fumarate and cyclodextrin.As compared with prior bencyclane fumarate preparations, this composition can greatly decrease the adverse effects of bencyclane fumarate and, in addition, offers considerable advantages from the viewpoints of method of use and method of production of preparation.

Abstract: A low pressure cordless and tubeless tire is provided in the vicinity of the widest portion of the tire body with annular reinforcement ribs extending continuously or discontinuously along the entire circumference of the tire body at the side walls. Adjacent the first annular ribs are second annular ribs located between the side walls and the shoulder region of the tread section. The first and second ribs at each side wall define an annular groove therebetween.

Abstract: A method for preparing a stable urokinase injection by the liophilization of urokinase which comprises liophilizing an aqueous solution containing urokinase, human serum albumin and one or more amino acid compounds selected from polar amino acids and salt thereof. The urokinase injection obtained according to this method is excellent in the storing stability as compared with conventional urokinase preparations for injection.

Abstract: A process for freeze-drying a penicillin derivative of the formula: ##STR1## wherein R is a hydrogen atom or a hydroxyl group, by evaporating a frozen aqueous solution of the penicillin derivative (I) under vacuum from the frozen state to dryness, which is characterized by maintaining the temperature of the frozen solution within a range from the eutectic point of the solution determined by the electric resistance method to -8.degree. C. when the penicillin derivative of the formula (I) wherein R is a hydrogen atom is to be freeze-dried, or -10.degree. C. when the penicillin derivative of the formula (I) wherein R is a hydroxyl group is to be freeze-dried during the primary drying period of the drying process.